GDC-1971 + Atezolizumab for Advanced Solid Cancers
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, GDC-1971, combined with an existing treatment, atezolizumab, in patients with advanced or spreading solid tumors. It includes specific cancers like certain lung cancers, head and neck cancers, and melanoma. The goal is to see if this combination can better help the immune system find and destroy cancer cells. Atezolizumab is an immune checkpoint inhibitor that has shown efficacy in combination with other treatments for various cancers.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, since the trial involves new treatments, it's possible that some medications might need to be adjusted. Please consult with the trial coordinators for specific guidance.
What data supports the idea that GDC-1971 + Atezolizumab for Advanced Solid Cancers is an effective drug?
The available research shows that Atezolizumab, when used alone, has shown effectiveness in treating advanced bladder cancer and non-small cell lung cancer. For bladder cancer, it improved survival rates and had a favorable safety profile. In lung cancer, it extended survival compared to another drug, docetaxel. However, there is no specific data provided on the combination of GDC-1971 and Atezolizumab for advanced solid cancers, so we can't directly assess its effectiveness from the information given.12345
What safety data is available for the treatment with GDC-1971 and Atezolizumab?
Atezolizumab, also known as Tecentriq, has been evaluated in several clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC), urothelial carcinoma, and bladder cancer. The safety profile of Atezolizumab has been deemed acceptable, with common adverse reactions including fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation. More severe grade 3 to 4 adverse events include dyspnea, pneumonia, hypoxia, hyponatremia, fatigue, anemia, musculoskeletal pain, and liver enzyme increases. Immune-related adverse events such as pneumonitis, hepatitis, colitis, and thyroid disease have been observed in a small percentage of patients. The safety data for GDC-1971 specifically is not detailed in the provided research, but Atezolizumab's safety profile is well-documented across multiple studies.12356
Is the drug Atezolizumab, used in the trial GDC-1971 + Atezolizumab for Advanced Solid Cancers, a promising treatment?
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for adults with certain advanced solid tumors, including specific types of lung cancer, head and neck cancer, and melanoma. Participants should be in good physical condition (ECOG 0 or 1), have a life expectancy of at least 12 weeks, no prior treatments for their advanced cancer, and meet specific genetic markers like PD-L1 positivity.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Atezolizumab (Monoclonal Antibodies)
- GDC-1971 (Other)
- Omeprazole (Other)
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Genentech, Inc.
Lead Sponsor